• Nuclear cGAS Restricts L1 Retrotransposition

  2026-09-17

  The reference study identifies a posttranslational mechanism in which nuclear cGAS promotes TRIM41-dependent ubiquitination and degradation of L1 ORF2p, thereby limiting retrotransposition and protecting genome integrity. It further connects DNA damage–activated Chk2 phosphorylation of cGAS to this pathway, providing a mechanistic framework for studying L1 control in senescence and tumorigenesis.

• Shrimp STING and the Evolution of DNA Antiviral Sensing

  2026-09-16

  The reference study shows that shrimp STING can bind both double-stranded DNA and cyclic dinucleotides, linking pathogen nucleic-acid recognition to an IFN-like antiviral response. Its proposed DNA–STING–IKKε–IRF–Vago4 axis expands current models of innate immune evolution by identifying direct DNA sensing through STING in an arthropod.

• 6-OHDA Hydrochloride: Mechanism and Model Design

  2026-09-16

  6-OHDA hydrochloride is a powerful tool for creating targeted catecholaminergic neurodegeneration models. This guide connects its redox biology and transporter-dependent uptake with a protein-corona study, showing how to design more interpretable lesion, cellular, and delivery assays.

• HDAC6, α-Tubulin Lactylation, and Microtubules

  2026-09-15

  The reference study identifies α-tubulin K40 lactylation as a metabolism-sensitive post-translational modification that increases microtubule dynamics in neurons. It further establishes HDAC6 as a primary lactylation writer, linking intracellular lactate, cytoskeletal behavior, and neurite development through a reversible regulatory mechanism.

• TCF25, Lysosomal Acidification, and Starvation Cell Death

  2026-09-15

  Ren et al. identify TCF25 as a nutrient-responsive regulator that links glucose starvation to V-ATPase-dependent lysosomal acidification, autophagy, ferritinophagy, and lysosome-dependent cell death. The study provides a mechanistic framework for understanding how lysosomes first preserve energy balance and later contribute to tissue injury during prolonged nutrient stress.

• PP2A, Autophagy, and Candida Biofilm Resistance

  2026-09-14

  The reference study identifies PP2A-dependent ATG protein phosphorylation as a mechanistic link between autophagy, Candida albicans biofilm formation, and reduced antifungal efficacy. Its combination of PPH21 disruption, rapamycin-mediated autophagy activation, molecular analysis, and an oral infection model provides a useful framework for antifungal drug resistance research.

• DiD (DiDC 18 (5)) for Cell Tracking

  2026-09-13

  DiD (DiDC 18 (5)) is a red fluorescent membrane probe for resolving cell position, migration, adhesion, and fusion in complex samples. This guide develops an assay-design framework linking membrane tracking to the ROS-driven macrophage biology described in diabetic periodontitis research, while clearly defining interpretation limits.

• Cy3-dCTP for Direct Fluorescent DNA Labeling

  2026-09-12

  Cy3-dCTP, also called Cyanine 3-deoxycytidine triphosphate, is a fluorescent dCTP analog for direct enzymatic labeling of DNA and cDNA. Product specifications support PCR and Nick Translation workflows with a 30–50% Cy3-dCTP to 50% dCTP starting ratio, while polymerase compatibility and labeling density remain assay-dependent.

• Ridaforolimus (Deforolimus) Research Workflow

  2026-09-12

  Ridaforolimus enables mechanism-first studies of mTOR signaling, cancer-cell proliferation, metabolism, and VEGF output. This practical workflow connects pathway biomarkers with viability, apoptosis, angiogenesis, and carefully controlled senescence assays.

• Testosterone Bounce in Degarelix-Treated Prostate Cancer

  2026-09-11

  This retrospective study identified a testosterone bounce, defined by recovery from a nadir below 20 ng/dL to a subsequent value of at least 20 ng/dL, as a marker associated with longer overall and cancer-specific survival during degarelix therapy. The finding suggests that serial testosterone kinetics may complement PSA-based assessment, although external validation is needed before clinical use.

• Low-Dose Cadmium Activates STAT3 in Lymphangiogenesis

  2026-09-11

  The reference study identifies a previously underappreciated effect of low-dose cadmium on lymphatic vessel growth after corneal injury. Using mouse and human dermal lymphatic endothelial cell models, the authors link cadmium exposure to STAT3 activation, VEGFR3 induction, and dose-dependent changes in endothelial proliferation and migration.

• Deferasirox and the Lysosomal Iron-Stress Switch

  2026-09-10

  The 2025 TCF25 study reframes lysosomal iron as a context-dependent determinant of survival during glucose starvation. This article translates that mechanism into a rigorous Deferasirox research strategy while separating established chelation biology from testable hypotheses in cancer, ischemia, and nutrient-stress models.

• GSK 2837808A: LDHA Inhibition Workflows

  2026-09-10

  GSK 2837808A is a potent lactate dehydrogenase A inhibitor for separating LDHA-dependent lactate output from broader glycolytic behavior. This article provides practical assay workflows, controls, troubleshooting guidance, and a hypothesis-driven bridge from hepatocellular carcinoma research to the NAT1–ENO1–lactate–PD-L1 axis in colorectal cancer.

• Baicalin Methyl Ester and LPS-Induced Barrier Damage

  2026-09-09

  A 2024 Biomedicine & Pharmacotherapy study shows that baicalin methyl ester protects murine intestinal tissue and MODE-K epithelial cells from LPS-associated barrier injury through the P65/TNF-α/MLCK/ZO-1 axis. The work combines animal, cell-based, protein-expression, docking, and immunoprecipitation evidence, while also defining experimental dose ranges relevant to intestinal inflammation research.

• Paroxetine Mesylate: Assay Design for Repurposing

  2026-09-09

  Paroxetine Mesylate is a Selective serotonin reuptake inhibitor with a broader pharmacology than its psychiatric indication suggests. This article presents an assay-centered framework for interpreting its SERT, CYP2D6, MET, and ERBB3 activities in colorectal cancer research without confusing phenotypic data with clinical proof.

8681 records 6/579 page Previous Next First page 上5页 678910 下5页 Last page